- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02840409
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Emily Taylor
- Phone Number: 201353 416-813-7654
- Email: emilyl.taylor@sickkids.ca
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia
- Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia
- Queensland Children's Hospital
-
-
South Australia
-
North Adelaide, South Australia, Australia
- Women's and Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australia
- Royal Children's Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia
- Perth Children's Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada
- Stollery Children's Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- BC Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Cancer Care Manitoba
-
-
Ontario
-
Hamilton, Ontario, Canada
- McMaster Children's Hospital
-
London, Ontario, Canada
- Children's Hospital - London Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Quebec
-
Montréal, Quebec, Canada
- Montreal Children's Hospital
-
Montréal, Quebec, Canada
- Centre Hospitalier Universitaire Sainte-Justine
-
Québec, Quebec, Canada
- CHU du Quebec-Universite Laval
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand
- Starship Children's Hospital
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- The Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children and adolescents aged 6 months to < 18 years old with Low Grade Glioma (See Appendix I).
- All patients must submit tumour tissue (fresh tumour tissue is recommended) and have pathological confirmation of LGG and determination of BRAF characteristics from the Hospital for Sick Children. Exceptions will be made for patients with neurofibromatosis type 1 who have not previously had a biopsy. NF1 patients are eligible without tissue confirmation but must have definitive clinical or radiographic evidence of tumour progression or risk for significant neurologic deterioration requiring immediate therapy. If a tissue sample for NF1 patients is available from a previous biopsy, it is required to be submitted for Central Review at the Hospital for Sick Children. Please refer to the lab manual for further details.
- Patients must have progressive disease following surgical excision based on clear radiological or clinical evidence of progression, or an incomplete excision (< 95% or > 1.0 cm2 residual tumour) with necessity to begin treatment because of a risk of neurological impairment with progression.
- All patients on study must have measurable tumour (>1.0 cm2 of residual tissue if resection has been performed) within 28 days of enrollment.
- Patients must have received no prior therapy including chemotherapy, biological modifiers and/or radiation treatment for the tumour with the exception of surgery.
- Patient is able to start treatment within 14 working days after randomization.
- Post pubertal teenagers who are sexually active agree to use two methods of contraception during the treatment period and for at least 6 months after the last dose of study drug. Please refer to Appendix V for a list of acceptable methods of contraception.
- Lansky performance status > 50% for patients < 16 years of age. Karnofsky performance status > 50% for patients ≥ 16 years of age.
- Patients with neurologic deficits must have deficits that are stable for a minimum of 1 week prior to enrollment.
- Patients receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment.
- Life expectancy > 2 months at the time of enrollment.
- Parents/guardians must provide written informed consent and to agree that they (and the patient) will comply with the study protocol.
- Written assent by patient according to institutional guidelines.
Patients must have adequate bone marrow function within 2 weeks prior to enrollment:
- Hemoglobin ≥ 10 g/dL (may be supported )
- Neutrophil count ≥ 1.0 × 109/L
- Platelet count ≥ 100 × 109/L (transfusion independent)
- Patients not on a therapeutic dose of an anti-coagulant must have an INR ≤ 1.5 and an aPTT ≤ 1.5x institutional ULN for age within 2 weeks prior to enrollment. Anti-coagulation is permitted prior to enrollment on the condition that the patient is, according to the local clinical practice guidelines or approved product labeling, adequately anti-coagulated prior to enrollment.
Patients must have satisfactory liver function within 2 weeks prior to enrollment:
- AST ≤ 3x institutional ULN for age
- ALT ≤ 3x institutional ULN for age
- Total Bilirubin ≤ 1.5x institutional ULN for age
Patients must have satisfactory renal parameters and meet the following criteria within 2 weeks prior to enrollment :
- Serum creatinine must be ≤ 1.5x ULN for age. If the serum creatinine is > 1.5 × ULN, the glomerular filtration rate (either estimated or formal) must be >90 mL/min/1.73 m2, for patient to be enrolled.
- Absence of clinically significant proteinuria, as defined by screening of the early morning urine (urine protein < 1g/L and/or albumin/creatinine ratio < 1.0 (mg/mmol)). If urine protein ≥ 1g/L, then Urine Protein Creatinine (UPC) ratio should be calculated. If UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg/24 hours for patient enrollment. Note: UPC ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 g. UPC ratio is calculated using one of the following formulas:
[urine protein]/[urine creatinine] - if both protein and creatinine are reported in mg/dL or [(urine protein) x0.088]/[urine creatinine] - if urine creatinine is reported in mmol/L
Quality of Life Correlative Study Inclusion Criteria (Optional):
- Age ≥ 3 and < 18 years.
- English- or Spanish-speaking.
- No known history of a significant neurodevelopmental disorder prior to diagnosis of LGG (e.g., Down syndrome, Fragile X, William's Syndrome, mental retardation). Patients with NF1 are not excluded.
- No significant motor or sensory impairment that would prevent computer use and perception of the visual and auditory test stimuli.
Exclusion Criteria:
- Children under 6 months of age.
- Pregnant or lactating females.
- Use of any investigational agent, systemic, targeted or immunotherapy prior to the first dose of study treatment.
- Any bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation).
- Patients with evidence of new symptomatic CNS hemorrhage (> grade I) on baseline MRI.
- Any significant cardiovascular disease, e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis, CVAs, transient ischemic attacks (TIAs), and systemic hypertension (i.e., a systolic and diastolic BP ≥ 95th percentile for age, sex), prior history of hypertensive crisis or hypertensive encephalopathy or stroke, uncontrolled cardiac arrhythmia within 6 months prior to enrollment .
- Any previous venous thromboembolism Grade 3 or higher (NCI CTCAE v. 4.03).
- History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment.
- Unresolved infection.
- An active peptic or duodenal ulcer.
- Major surgical procedure (see Table 3 section 6.1.7), brain surgery, open biopsy or significant traumatic injury within 28 days prior to enrollment or the anticipation of the need for major (elective) surgery during the course of the study treatment.
- Intermediate surgical procedure (see Table 3 section 6.1.7) within 2 weeks of enrollment.
- Minor surgical procedures (see Table 3 section 6.1.7) within 3 days prior to the start of treatment (including the placement of a central line, including PICC line). Insertion of a port-a-cath will require a 7-day interval prior to the start of treatment.
- Non-healing surgical wound.
- A bone fracture that has not satisfactorily healed.
Concomitant use of the following:
- Aspirin (> 325mg/day) within 10 days of enrollment
- Clopidogrel (> 75mg/day) within 10 days of enrollment
- Use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes with INR and aPTT outside therapeutic standards according to institutional guidelines within 10 days of first dose of Bevacizumab. Note: The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of the Baseline Visit. Prophylactic use of anticoagulants is allowed.
- Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
68 weeks of single agent Vinblastine administered once weekly IV
|
|
Experimental: Arm B
68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of the addition of Bevacizumab to Vinblastine compared with Vinblastine alone in chemotherapy-naïve pediatric patients with unresectable or progressive Low Grade Gliomas as measured by Response Rate (RR).
Time Frame: 6 months from randomization
|
Objective response rate within 6 months of randomisation
|
6 months from randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine 6 month, 12 month and 2 year progression free survival (PFS) between vinblastine alone versus in combination with Bevacizumab.
Time Frame: At 6 and 12 months and 2 years
|
Optical Coherence Tomography (OCT) should occur in conjunction with the Visual Field/Acuity exams for participating institutions equipped with OCT.
|
At 6 and 12 months and 2 years
|
To determine if the prevalence of cognitive deficits in children and adolescents treated for LGG, is significantly higher than the normative population (> 14%) using the NIH Toolbox Cognitive Battery.
Time Frame: At 1 year off therapy
|
Domains include: working memory, executive function, processing speed, episodic memory, and attention
|
At 1 year off therapy
|
To determine the effects of Bevacizumab on cognitive function in the pediatric population using the NIH Toolbox Cognitive Battery.
Time Frame: During treatment, 28 days after completing treatment, at 6 months and 1 year off therapy
|
The effects of Bevacizumab on cognitive function in the pediatric
|
During treatment, 28 days after completing treatment, at 6 months and 1 year off therapy
|
To determine if the prevalence of QOL difficulties in children and adolescents treated for LGG at 1 year off therapy, is significantly higher than the normative population (> 14%).
Time Frame: At 1 year off therapy
|
Domains include: fatigue, physical activity, anxiety, depression, and peer relationships.
|
At 1 year off therapy
|
Overall survival (OS) at the end of study.
Time Frame: From the date of study completion (approximately 6.5 years (78 months)) up till the date of death.
|
overal survival at 5 years post randomisation
|
From the date of study completion (approximately 6.5 years (78 months)) up till the date of death.
|
To evaluate the difference in visual outcome measures in children with optic pathway gliomas treated with vinblastine alone or in combination with Bevacizumab.
Time Frame: Every 3 months during treatment, every 3 months for 1 year after completion of treatment, then every 6 months for 4 years.
|
visual acuity measure with Teller Grading Acuity
|
Every 3 months during treatment, every 3 months for 1 year after completion of treatment, then every 6 months for 4 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the effect of Bevacizumab on growth and puberty by recording patient's height and using the Tanner Scale to measure puberty.
Time Frame: Baseline, 28 days off therapy, and then annually for 5 years off therapy
|
Growth will be analyzed by recording patient's height, following treatment until completion of puberty.
Puberty will be measured using the Tanner Scale where Tanner stage V for pubic hair, breast, and genitalia represent mature development and completion of puberty.
|
Baseline, 28 days off therapy, and then annually for 5 years off therapy
|
To evaluate the safety of the combination of Vinblastine and Bevacizumab compared with Vinblastine alone in pediatric patients with LGG, focusing on serious adverse events as assessed by CTCAE v 4.03.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Collection of Adverse events in the bevacizumab arm
|
Through study completion which is approximately 6.5 years (78 months)
|
To define and describe the toxicities of the agents in combination and of single agent Vinblastine in this treatment naïve population as assessed by CTCAE v 4.03.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Collection of Adverse events in the vinblastine arm
|
Through study completion which is approximately 6.5 years (78 months)
|
To evaluate the effect of Bevacizumab on fertility. This includes the risk of delay in pubertal development as well as abnormal menstrual status and the risk of primary or secondary amenorrhea and later on the potential effect on pregnancies) assessed by
Time Frame: Baseline, 28 days off therapy, and then annually for 5 years off therapy
|
Follow-up of patients regardign fertility
|
Baseline, 28 days off therapy, and then annually for 5 years off therapy
|
To prospectively determine the role of BRAF mutation/fusion in PLGG and correlate this with outcome and response to therapy.
Time Frame: Tissue will be submitted prior to study registration for pathology review.
|
Evaluation fo response according to molecular status of the tumour
|
Tissue will be submitted prior to study registration for pathology review.
|
To determine the presence and prognostic significance of other mutations, including RAF1, FGFR1, MYB, MYBL1, PTPN11, NTRK2, H3F3A, ATRX and CDNK2A deletions among others.
Time Frame: Blood samples will be collected at Baseline.
|
Evaluation fo biomarkers in the blood
|
Blood samples will be collected at Baseline.
|
To stratify PLGG based on methylation profile, using methylation arrays.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Analysis of methylation profile
|
Through study completion which is approximately 6.5 years (78 months)
|
To determine demographic (e.g., SES, gender), disease (e.g., risk status), treatment, and behavioral predictors of neurocognitive and QOL deficits as measured by the NIH Toolbox Cognitive and PROMIS batteries in children and adolescents with LGG.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Evaluation of cognitive impact of treatment
|
Through study completion which is approximately 6.5 years (78 months)
|
To determine the prevalence of cognitive deficits in PLGG population.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Evaluation of cognitive impact of tumour and treatment
|
Through study completion which is approximately 6.5 years (78 months)
|
To examine the role of vascularity (including MVD) in PLGG and investigate potential biomarkers to assist in determining the population of best responders to anti-angiogenic therapy in PLGG.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Analysis of biomarkers of angiogenesis
|
Through study completion which is approximately 6.5 years (78 months)
|
To assess the use of novel MR biomarkers to assess disease response in these patients and to correlate these with traditional imaging tools.
Time Frame: Through study completion which is approximately 6.5 years (78 months)
|
Evaluation of MRI biomarkers of response
|
Through study completion which is approximately 6.5 years (78 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Eric Bouffet, MD, The Hospital for Sick Children
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Vinblastine
Other Study ID Numbers
- 1000052116
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Grade Glioma
-
National Cancer Institute (NCI)RecruitingLow Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade GliomaUnited States, Canada, Puerto Rico
-
St. Jude Children's Research HospitalSpringWorks Therapeutics, Inc.RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Neurological Associates of West Los AngelesEnrolling by invitationLow Grade Glioma of BrainUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Massachusetts General HospitalNational Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | WHO Grade 3 Glioma With IDH1 Mutation | WHO Grade 3 Glioma With 1p/19q CodeletionUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part SarcomaUnited States